Magazine Article | November 1, 2022

Can We Accelerate Biosimilars Development Without Compromising Quality Or Safety?

Source: Life Science Leader

By Tim Lowery

The biosimilar path to commercialization is inherently complex, which means products take longer to produce and cost more than generic versions of conventional drugs. I recently sat down with John Gabrielson from Similis Bio to discuss how our industry is working to navigate these issues. One recent proposal, published in Science, called for an end to the use of animal toxicity studies in biosimilar development. The author reasoned, in part, that because biosimilars are engineered from living cells, and animals do not have the same receptors that humans do, there are no true results in this process.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader